The EU's pharmaceutical legislation is undergoing its biggest overhaul in more than two decades. Discover the key changes, implementation timeline, incentives, regulatory reforms and what pharma and biotech companies need to do now.
The European Union is entering a new era for pharmaceutical regulation.
Following more than two years of legislative negotiations, the European Parliament and the Council reached a political agreement on 11 December 2025 on the EU's new pharmaceutical legislation — widely referred to as the "Pharma Package." The reform represents the most significant overhaul of the EU pharmaceutical regulatory framework in more than two decades.
The reform will replace the core EU pharmaceutical legislation that has governed medicines for more than 20 years, including Regulation (EC) No 726/2004 and Directive 2001/83/EC, while also replacing the existing legislation covering orphan and paediatric medicines. It will also introduce targeted amendments to legislation covering advanced therapy medicinal products, clinical trials and EMA's mandate.
For pharmaceutical and biotechnology companies, this is much more than a legislative refresh.
The new framework has the potential to influence R&D strategy, regulatory development, market exclusivity, orphan medicines, paediatric development, clinical development, manufacturing, supply chains, environmental obligations and market access across Europe.
The existing EU pharmaceutical framework was largely established in the early 2000s.
Since then, the pharmaceutical industry has changed dramatically.
The development ecosystem has become increasingly global, while technologies such as:
have created new scientific and regulatory challenges.
At the same time, Europe faces persistent issues around medicine shortages, uneven access to innovative medicines, antimicrobial resistance and competitiveness of the European life sciences sector.
The new legislation is intended to address these challenges while maintaining Europe's high standards for quality, safety and efficacy.
The reform is broad, but several areas are particularly important for pharma and biotech companies.
One of the most commercially important aspects of the reform is the new approach to regulatory data and market protection.
Under the agreed framework, innovative medicines will receive:
8 years of regulatory data protection, followed by:
1 year of market protection, with opportunities for additional protection where specified criteria are met.
An additional year of market protection may be available for innovative medicines satisfying defined conditions, while another year may be available for medicines with an additional indication.
The overall maximum combined protection period can reach 11 years in certain circumstances.
This represents a significant consideration for companies when modelling the commercial lifecycle of new medicines.
For innovative pharma and biotech companies, the implications extend beyond regulatory strategy into:
The commercial value of a regulatory strategy will increasingly depend on understanding how these protection mechanisms interact with the development plan.
Rare diseases are another important area of reform.
The new framework seeks to encourage investment in orphan medicines through stronger incentives and earlier regulatory support.
Companies developing promising orphan medicines may benefit from early regulatory guidance, potentially well before marketing authorisation, helping developers identify regulatory challenges earlier in the development programme.
The framework also provides the possibility of significant regulatory protection for orphan medicines.
For certain breakthrough orphan medicines addressing unmet medical needs, the combined protection period can reach up to 11 years.
For biotech companies operating in rare disease, this could become an important component of development and investment strategy.
Antimicrobial resistance remains one of Europe's major public health challenges.
The Pharma Package introduces a new incentive designed to encourage development of priority antibiotics through a transferable exclusivity voucher.
The voucher can provide one additional year of market protection for another pharmaceutical product and may itself be transferred or sold.
The agreed framework also introduces safeguards around its use, including a limitation intended to protect healthcare budgets by preventing the voucher from being used on products exceeding a specified sales threshold.
This is a significant development because traditional commercial incentives have often been insufficient to support antibiotic R&D.
The new mechanism attempts to create a financial incentive while recognising the unique economics of antimicrobial development.
The new legislation is also intended to modernise the European regulatory system itself.
EMA has highlighted several objectives, including:
The reform will also involve changes to EMA's scientific committee structure and procedures.
For sponsors, this could ultimately translate into a more streamlined regulatory experience.
However, the practical impact will depend heavily on the implementing legislation, guidance, procedures and IT systems that are developed during the transition period.
Medicine shortages have become an increasingly important issue across Europe.
The new legislation strengthens requirements around shortage prevention and supply security.
Companies will face enhanced expectations around:
The legislation also gives Member States additional powers to require companies benefiting from regulatory protection to supply certain medicines in sufficient quantities to meet patient needs.
For pharmaceutical companies, supply chain strategy is therefore becoming increasingly integrated with regulatory strategy.
Manufacturing resilience, API sourcing, supply forecasting and shortage management will need to be considered alongside traditional regulatory planning.
Environmental considerations are becoming increasingly embedded within European pharmaceutical regulation.
The new framework strengthens the role of environmental risk assessment (ERA) and risk mitigation.
This is particularly relevant for:
For companies, environmental requirements should increasingly be considered early in development rather than treated as a late-stage regulatory activity.
Digital transformation is another central theme.
EMA has identified digitalisation as one of the strategic priorities underpinning implementation of the new legislation.
For sponsors, this reinforces a broader direction already visible across the European regulatory environment:
Regulatory processes are becoming increasingly digital, data-driven and interconnected.
Companies should therefore expect greater emphasis on:
This creates an opportunity for companies to modernise their regulatory information management strategies alongside the legislative transition.
Understanding the implementation schedule is critical.
The reform does not become operational overnight.
The European Commission published its proposal for a comprehensive reform of EU pharmaceutical legislation in April 2023.
The European Parliament adopted its negotiating position in April 2024.
The Council of the EU adopted its negotiating position in June 2025.
The European Parliament and Council reached a political agreement on the final shape of the new pharmaceutical legislation.
This was described by EMA as the most significant overhaul of the EU medicines regulatory framework in more than two decades.
The legislative texts move through formal adoption, followed by publication in the Official Journal.
EMA's implementation programme is already underway, with dedicated governance and workstreams established across areas including:
The period following entry into force is expected to be used for implementation.
During this period:
EMA currently identifies 2028 as the point at which the new pharmaceutical legislation becomes applicable, following the transition period.
Some provisions may apply earlier, including certain measures relating to regulatory sandboxes and antimicrobial-resistance incentives.
For established pharmaceutical companies, the reform should not be viewed simply as a future compliance exercise.
It creates an opportunity to reassess the entire product lifecycle.
Companies should consider the potential impact on:
Future EU submissions will need to be planned against a changing regulatory framework.
Companies with products currently in development should assess whether upcoming applications will fall under the existing or new framework.
The new incentives may influence decisions around:
Regulatory strategy and development strategy will become even more closely connected.
Changes to regulatory and market protection could have a direct impact on:
Companies should model these scenarios well before key patent and exclusivity milestones.
The stronger focus on shortages means regulatory, manufacturing and supply chain teams will need to work more closely together.
For critical medicines in particular, companies should assess whether their current supply strategies will meet the future requirements.
The reform could be particularly important for emerging biotech companies.
Smaller companies often face disproportionate challenges in navigating complex regulatory systems and financing long development programmes.
The new framework's focus on:
could provide valuable opportunities for innovative biotech developers.
For biotech, however, regulatory strategy should begin much earlier.
The decisions made during early development could influence eligibility for incentives, regulatory support and future market protection.
Although broad application is expected in 2028, waiting until 2028 to prepare would be a mistake.
Identify products potentially affected by:
For assets in Phase I–III development, assess whether the new framework creates opportunities to optimise:
The transition period will generate substantial volumes of:
Companies will need a structured process for monitoring and interpreting these developments.
The direction of travel is clearly toward earlier regulatory interaction and development support.
Sponsors should consider how available advice mechanisms can be integrated into development programmes.
The move toward greater digitalisation means companies should assess whether their regulatory information management, submission and product information systems are ready for the future framework.
The EU Pharma Package is being introduced at a time when Europe is competing globally for pharmaceutical R&D, manufacturing investment and biotechnology innovation.
The legislation therefore needs to be viewed in a wider strategic context.
The EU is attempting to achieve several objectives simultaneously:
Improve patient access.
Strengthen innovation.
Maintain Europe's competitiveness.
Reduce medicine shortages.
Address antimicrobial resistance.
Modernise regulatory processes.
Strengthen the resilience of the European pharmaceutical ecosystem.
The challenge will be finding the right balance between these objectives.
EMA has already established a dedicated governance structure for implementation of the new legislation.
The Agency is working with the European Commission, national competent authorities and stakeholders to prepare the necessary guidance and operational changes.
This means the next two years will be particularly important.
For industry, the most valuable regulatory intelligence may increasingly come not simply from the legislation itself, but from the implementation guidance and practical interpretation that follows.
The revision of EU pharmaceutical legislation represents a fundamental reset of Europe's medicines regulatory framework.
The December 2025 political agreement marked the end of a lengthy negotiation process. The focus now shifts from policy design to implementation.
For pharma and biotech companies, the next phase is therefore critical.
The organisations that begin assessing the impact now will be better positioned to take advantage of new incentives, anticipate compliance requirements and optimise their development and regulatory strategies.
The message for industry is clear:
2028 may be the year the new rules broadly apply — but preparation needs to start now.
Regvista supports pharmaceutical and biotechnology companies in translating regulatory change into practical development and registration strategies.
From portfolio impact assessments and orphan strategies to EU regulatory pathways, lifecycle management and implementation readiness, early strategic planning can help organisations turn regulatory change into a competitive advantage.
At Regvista, we remain committed to support biopharmaceutical leaders navigating their transformative journey—bringing cutting-edge therapies to market faster and safer. Please feel free to contact us by submitting your enquiry to deployment@regvista.co.uk
02-Aug-26